Head-to-head evidence
dapiglutide vs elecoglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
dapiglutide
Developed by Zealand Pharma
NCT06758583 · Phase 1 · completed
Both groups received active dapiglutide at different concentrations with no placebo or blinding, and the study measured only drug levels in the blood rather than a clinical effect. No results have been posted.
elecoglipron
Developed by AstraZeneca
NCT06579092 · Phase 2 · completed
This randomised, triple-blind, placebo-controlled trial in 310 adults living with obesity or overweight reported a 10.5% reduction in body weight on elecoglipron 75 mg against 0.6% on placebo at 26 weeks. Percent weight change is the measure regulators accept as the primary efficacy endpoint in obesity.
Next expected readout: April 2028 · NCT07775404 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dapiglutide's landscape · elecoglipron's landscape